Abstract
Thrombolytic therapy with alteplase in acute ischemic stroke is currently established within 3 h from symptom onset in carefully selected patients. Expansion of the time window is being assessed in trials with alteplase and desmoteplase. Also, tenecteplase, reteplase and staphylokinase are being evaluated in stroke patients. A better understanding of the coagulation and fibrinolytic systems may provide insight into drug development, interactions, complications, and may ultimately improve patient triage and treatment regimens. Future adjuvant and additional therapies could prove useful for patients who do not benefit from standard thrombolytic treatment or may augment the overall gain.
Keywords: Thrombolytic therapy, stroke, cerebral infarction, t-PA, thrombolysis, hemorrhage, recanalization, thrombosis
Current Vascular Pharmacology
Title: Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Volume: 4 Issue: 1
Author(s): Atte Meretoja and Turgut Tatlisumak
Affiliation:
Keywords: Thrombolytic therapy, stroke, cerebral infarction, t-PA, thrombolysis, hemorrhage, recanalization, thrombosis
Abstract: Thrombolytic therapy with alteplase in acute ischemic stroke is currently established within 3 h from symptom onset in carefully selected patients. Expansion of the time window is being assessed in trials with alteplase and desmoteplase. Also, tenecteplase, reteplase and staphylokinase are being evaluated in stroke patients. A better understanding of the coagulation and fibrinolytic systems may provide insight into drug development, interactions, complications, and may ultimately improve patient triage and treatment regimens. Future adjuvant and additional therapies could prove useful for patients who do not benefit from standard thrombolytic treatment or may augment the overall gain.
Export Options
About this article
Cite this article as:
Meretoja Atte and Tatlisumak Turgut, Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts, Current Vascular Pharmacology 2006; 4 (1) . https://dx.doi.org/10.2174/157016106775203108
DOI https://dx.doi.org/10.2174/157016106775203108 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atorvastatin Inhibits Advanced Glycation End Products (AGE)-Induced C-Reactive Expression in Hepatoma Cells by Suppressing Reactive Oxygen Species Generation
Vascular Disease Prevention (Discontinued) Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism The Emergence of Plasma Membrane Calcium Pump as a Novel Therapeutic Target for Heart Disease
Mini-Reviews in Medicinal Chemistry Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design Risk Factors for Ischemic Heart Disease
Reviews on Recent Clinical Trials Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Trends in Metabolic Syndrome and Gene Networks in Human and Rodent Models
Endocrine, Metabolic & Immune Disorders - Drug Targets The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry von Willebrand Factor, von Willebrand Factor-Cleaving Protease, and Shear Stress
Cardiovascular & Hematological Agents in Medicinal Chemistry Brain Angiotensin and Cardiovascular Reactivity to Negative and Positive Emotional Stress
Current Hypertension Reviews Chemodiversity in Freshwater and Terrestrial Cyanobacteria – A Source for Drug Discovery
Current Drug Targets Conduction Disorders: The Value of Surface ECG
Current Cardiology Reviews Pathogenesis and Immune Status in COVID-19 Pneumonia - A Minireview
Coronaviruses The Role of Coagulation and Fibrinolysis in the Pathogenesis of Acute Lung Injury
Current Respiratory Medicine Reviews Markers of Systemic Inflammation in Obstructive Sleep Apnea Syndrome
Current Respiratory Medicine Reviews Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Current Pharmaceutical Design New Oral Anticoagulants for the Management of Heparin Induced Thrombocytopenia: A Focused Literature Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry